|
Dr. Thomas Jung
Chief Medical Officer
Thomas Jung brings significant experience in medical research and clinical development to Delenex. A board certified dermatologist, he has led research work in immunology at the Novartis Research Institute in Vienna, Austria, then spent nine years at Novartis in Basel.
In January 2008 he took the leadership of the Ilaris® development team, until its first marketing approval in 2009. Since then, he was part of the senior leadership team at the Novartis Institute for Biomedical Research (NIBR), most recently as EU Head of Translational Medicine.
|